First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat
STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for...